69 related articles for article (PubMed ID: 9531056)
21. Lipids and progression of renal disease: role of modified low density lipoprotein and lipoprotein(a).
Wanner C; Greiber S; Krämer-Guth A; Heinloth A; Galle J
Kidney Int Suppl; 1997 Dec; 63():S102-6. PubMed ID: 9407434
[TBL] [Abstract][Full Text] [Related]
22. Defensin promotes the binding of lipoprotein(a) to vascular matrix.
Bdeir K; Cane W; Canziani G; Chaiken I; Weisel J; Koschinsky ML; Lawn RM; Bannerman PG; Sachais BS; Kuo A; Hancock MA; Tomaszewski J; Raghunath PN; Ganz T; Higazi AA; Cines DB
Blood; 1999 Sep; 94(6):2007-19. PubMed ID: 10477730
[TBL] [Abstract][Full Text] [Related]
23. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
[TBL] [Abstract][Full Text] [Related]
24. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans.
Lavi S; McConnell JP; Rihal CS; Prasad A; Mathew V; Lerman LO; Lerman A
Circulation; 2007 May; 115(21):2715-21. PubMed ID: 17502572
[TBL] [Abstract][Full Text] [Related]
25. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2.
Lourida ES; Georgiadis AN; Papavasiliou EC; Papathanasiou AI; Drosos AA; Tselepis AD
Arthritis Res Ther; 2007; 9(1):R19. PubMed ID: 17326817
[TBL] [Abstract][Full Text] [Related]
26. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses.
Shi Y; Zhang P; Zhang L; Osman H; Mohler ER; Macphee C; Zalewski A; Postle A; Wilensky RL
Atherosclerosis; 2007 Mar; 191(1):54-62. PubMed ID: 16765356
[TBL] [Abstract][Full Text] [Related]
27. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.
Jabor B; Choi H; Ruel I; Hafiane A; Mourad W; Genest J
Can J Cardiol; 2013 Dec; 29(12):1679-86. PubMed ID: 24267807
[TBL] [Abstract][Full Text] [Related]
28. Atherothrombogenicity of lipoprotein(a): the debate.
Scanu AM
Am J Cardiol; 1998 Nov; 82(9A):26Q-33Q. PubMed ID: 9819101
[TBL] [Abstract][Full Text] [Related]
29. Utility of Lp-PLA2 in lipid-lowering therapy.
Racherla S; Arora R
Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
[TBL] [Abstract][Full Text] [Related]
30. OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways.
Wang WY; Li J; Yang D; Xu W; Zha RP; Wang YP
Cardiovasc Res; 2010 Mar; 85(4):845-52. PubMed ID: 19910444
[TBL] [Abstract][Full Text] [Related]
31. Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women.
Tzotzas T; Filippatos TD; Triantos A; Bruckert E; Tselepis AD; Kiortsis DN
Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):477-82. PubMed ID: 17928209
[TBL] [Abstract][Full Text] [Related]
32. Lipoprotein-associated phospholipase A2 levels are associated with erectile dysfunction in patients without known coronary artery disease.
Otunctemur A; Sahin S; Ozbek E; Cekmen M; İnal A; Tulubas F; Dursun M; Besiroglu H; Koklu I
Andrologia; 2015 Aug; 47(6):706-10. PubMed ID: 25091174
[TBL] [Abstract][Full Text] [Related]
33. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease.
Tsimikas S; Tsironis LD; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2094-9. PubMed ID: 17626905
[TBL] [Abstract][Full Text] [Related]
34. Enhanced binding of phospholipase-A2-modified low density lipoprotein by human adipocytes.
Natarajan MK; Fong BS; Angel A
Biochem Cell Biol; 1990 Nov; 68(11):1243-9. PubMed ID: 2125828
[TBL] [Abstract][Full Text] [Related]
35. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications.
Tabas I; Williams KJ; Borén J
Circulation; 2007 Oct; 116(16):1832-44. PubMed ID: 17938300
[TBL] [Abstract][Full Text] [Related]
36. Endothelial cells and atherosclerosis: lipoprotein metabolism, matrix interactions, and monocyte recruitment.
Saxena U; Goldberg IJ
Curr Opin Lipidol; 1994 Oct; 5(5):316-22. PubMed ID: 7858905
[TBL] [Abstract][Full Text] [Related]
37. Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells.
Higazi AA; Lavi E; Bdeir K; Ulrich AM; Jamieson DG; Rader DJ; Usher DC; Kane W; Ganz T; Cines DB
Blood; 1997 Jun; 89(12):4290-8. PubMed ID: 9192751
[TBL] [Abstract][Full Text] [Related]
38. Proliferative effect of phospholipase A2 on rat periacinar fibroblastoid cells of the pancreas.
Okumura Y; Shintani Y; Kato Y; Tamba J; Inoue H; Fujiyama Y; Bamba T
Pancreas; 1998 May; 16(4):505-10. PubMed ID: 9598812
[TBL] [Abstract][Full Text] [Related]
39. Extracellular matrix hyaluronan is a determinant of the endothelial barrier.
Qiao RL; Wang HS; Yan W; Odekon LE; Del Vecchio PJ; Smith TJ; Malik AB
Am J Physiol; 1995 Jul; 269(1 Pt 1):C103-9. PubMed ID: 7631735
[TBL] [Abstract][Full Text] [Related]
40. Dominant role of the C-terminal domain in the binding of apolipoprotein(a) to the protein core of proteoglycans and other members of the vascular matrix.
Scanu AM; Edelstein C; Klezovitch O
Trends Cardiovasc Med; 1999 Oct; 9(7):196-200. PubMed ID: 10881751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
